Adrenomedullin as a marker of severity in community acquired pneumonia
DOI:
https://doi.org/10.18203/2349-3291.ijcp20233243Keywords:
Community acquired pneumonia, Pro-adrenomedullin, WHOAbstract
Background: Stratification of the risk of mortality as well as identifying those patients most susceptible to complications due to pneumonia in the short and long-term, are key in establishing preventive strategies and optimizing treatment.
Methods: Cross Sectional Observational Study. Participants: 72 children of 1month to <18 years of suspected cases of community acquired pneumonia (CAP) were included according to World health organisation (WHO) criteria of pneumonia. Samples were taken at the outset for pro-Adrenomedullin (Pro-ADM) level estimation. Correlations between final clinical outcomes (viz. ICU Stay, mortality, length of hospital stay) with Serum Pro-ADM levels were noted.
Results: Significant positive correlation was seen between Pro-ADM levels (picomol/l) with duration of ICU stay (days), duration of invasive ventilation (days), duration of hospital stay (days) with correlation coefficient of 0.783, 0.778, 0.808 respectively. Pro-ADM levels at cut off point of >5.7 (picomol/l) with area under curve of 0.866 with diagnostic accuracy of 84.72% for correctly predicting severe CAP.
Conclusions: We concluded that pro-ADM levels found to be high in severe/very severe pneumonia patients as per WHO criteria. Also, in our study higher levels of pro-ADM at the outset suggests need of ICU, Ventilator or longer hospital stays.
Metrics
References
Courtais C, Kuster N, Dupuy AM. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2013;31(1):215-21.
Ghoshal AG. Burden of pneumonia in the country. J Assoc Physic India. 2020;12:23-9.
Jadavji T, Law B, Lebel MH, Kennedy WA, Gold R, Wang EE. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ. 1997; 156(5):S703-11.
Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011; 53(7):e25-76.
Nohynek H, Valkeila E, Leinonen M, Eskola J. Erythrocyte sedimentation rate, white blood cell count and serum C-reactive protein in assessing etiologic diagnosis of acute lower respiratory infections in children. Pediatr Infect Dis J. 1995;14(6):484-90.
España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, et al. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect. 2015;70(5):457-66.
Renaud B, Schuetz P, Claessens Y. Proadrenomedullin Improves Risk of Early Admission to ICU Score for Predicting Early Severe Community-Acquired Pneumonia. Chest. 2012;142:1447-54.
Bello S, Lasierra A B, Mincholé E. Prognostic power of Proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012;39:1144-55.
Das RR, Satapathy AK, Mukherjee A. Role of clinical criteria and oxygen saturation monitoring in diagnosis of childhood pneumonia in children aged 2 to 59 months. Indian Pediatr. 2021;58:1024-29.
Florin TA, Ambroggio L, Brokamp C. Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia. Clin Infect Dis. 2021;73(3):e524-30.
Furkan KM. Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients. Ann Clin Lab Sci. 2018;48(1):81-9.
Sardà SM, Hernández JC, Hernández-Bou S. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study. BMC Res. 2012;5:363.
Downloads
Published
How to Cite
Issue
Section
